Upadacitinib versus Infliximab Acute Severe Ulcerative Colitis Second-Line Treatment
Summary
A Phase 4 clinical trial (NCT07550673) is registered on ClinicalTrials.gov evaluating upadacitinib versus infliximab as second-line treatment for acute severe ulcerative colitis. The study title indicates a comparative effectiveness evaluation of these two biologic therapies for patients who have not responded to initial treatment. Trial details including eligibility criteria, enrollment status, and study locations can be accessed through the ClinicalTrials.gov registry.
About this source
GovPing monitors ClinicalTrials.gov - Phase 4 Trials for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 10 changes logged to date.
What changed
A new Phase 4 clinical trial registration has been posted to ClinicalTrials.gov under identifier NCT07550673. The study will compare upadacitinib against infliximab for treatment of acute severe ulcerative colitis in patients requiring second-line therapy. This is a standard clinical trial registry entry providing public access to research protocol information, sponsor details, and enrollment criteria.
Healthcare providers and pharmaceutical companies involved in inflammatory bowel disease treatment may need to monitor trial outcomes, as results could influence treatment guidelines and comparative effectiveness assessments for biologic therapies in ulcerative colitis management.
Archived snapshot
Apr 24, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Show glossary
Mentioned entities
Related changes
Get daily alerts for ClinicalTrials.gov - Phase 4 Trials
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from NIH.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ClinicalTrials.gov - Phase 4 Trials publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.